Summary.-This report gives the complete findings at one year of a study comparing radiotherapy (Rt) with radiotherapy followed by 3-drug chemotherapy (RtC3) in the treatment of histologically proven small-cell carcinoma of the lung of limited extent.
79%o of the Rt and 570% of the RtC3 patients developed distant metastases (P<0*0005).
At 12 months only 8oo of the Rt but 26°, of the RtC3 patients were alive and free of metastases.
Adverse reactions occurred much more frequently in the RtC3 series; 32% of the Rt series as against 83°' of the RtC3 series had reactions, the most common being nausea and vomiting (130, Rt, 710// RtC3) and the most serious being marrow depression (23o% Rt, 54 O/ RtC3).
No important differences were found among the survivors in the 2 series at 3, 6 or 12 months, in general condition, physical activity or respiratory function.
It is concluded that radiotherapy plus chemotherapy was superior to radiotherapy alone, although chemotherapy did not protect patients from recurrence of primary growth.
THE RESULTS of treatment of small-cell carcinoma of the lung are poor, with an overall 5-year survival of less than 1%.
Recent reports (Broder et al., 1977; Bunn et al., 1977) extensively review the literature. Failure to cure is largely related to the early appearance and thefrequency of metastases. Current therapeutic trials are almost all concerned with reducing this frequency.
A previous MRC study, conducted between 1962 and 1964, compared radiotherapy with surgery in operable patients with small-cell carcinoma. This showed a slightly improved survival for the radiotherapy series from 2 years (Medical Research Council, 1966) maintained to 10 years (Fox & Scadding, 1973) . However, both were localized treatments, and not directed at possible distant metastases. When the present study was initiated there was evidence from some studies (Bergsagel et al., 1972; Hansen et al., 1972; Eagan et al., 1973) , but not from others (Durrant et al., 1971; H0st, 1973) , that cytotoxic drugs, alone or in combination, given in addition to radiotherapy, could improve the survival ofpatients with smallcell carcinoma. The present study was therefore undertaken to examine in a randomized multicentre trial whether, in patients with "limited" disease ( clinical and radiographic evidence, was confined to the mediastinum, the soft tissues of one hemithorax, and the ipsilateral and contralateral scalene and lower cervical nodes. This "limited" disease could be encompassed by a pair of opposed radiation fields. Patients with a pleural efftision occupying less than one third of the thoracic cavity on the same side as the tumour were included. Patients were ineligible if they had received previous treatment with radiotherapy, cytotoxic chemotherapy or surgery (other than thoracotomy without resection), were over 70 years of age, had a blood-urea concentration over 60 mg/100 ml (8-4 mM) or had serious concomitant disease contraindicating radiotherapy or chemotherapy.
Histological diagnosis.-The diagnosis was made by the pathologist from the referring centre according to the WHO classification (Kreyberg et al., 1967 ) on a specimen obtained from bronchial, pleural, lung, mediastinal or cervical node biopsy, bronchial brushings or sputum cytology. All the specimens were later re-examined by a single reference pathologist for confirmation of the cell type.
Pretreatment investigations.-The pretreatment investigations included a posteroanterior chest radiograph, measurement of the haemoglobin and blood-urea concentrations, total white cell and platelet counts, and liver-function tests (serum concentration of bilirubin, alkaline phosphatase and alanine transaminase or equivalent enzyme).
Marrow examination and radioactive isotope scans for metastases were carried out routinely in only a few centres. The decision to admit a patient was not influenced by these findings.
Treatment. Appendix) .
Chemotherapy consisted of alternating 3-drug and 2-drug pulses at 3-week intervals for a total of 10 pulses. Cyclophosphamide 500 mg/mi2 plus methotrexate 50 mg/mi2 were given by i.v. injection at 3-week intervals for 10 pulses, 10 mg of metoclopramide being included in the injection as an antiemetic. CCNU (1 -(2 -chloroethyl) -3 -cyclohexyl-1-nitrosourea) 50 mg/mi2 was given orally on the first and alternating pulses thereafter, i.e. every 6 weeks for 5 pulses.
Initially chemotherapy was started as soon as possible after the end of the course of radiotherapy, but because of some episodes of severe toxicity the protocol was changed after the first 86 (46 Rt. 40 RtC3) patients had been entered. An interval of 3 weeks was introduced between the end of radiotherapy and the first pulse. The chemotherapy could be stopped before the completion of 10 pulses or prolonged beyond 10 pulses if the patient's progress warranted it.
Assessment of progress.-A report on each patient was completed at 3-week intervals for 30 weeks from the end of radiotherapy, and monthly thereafter. It included information on clinical assessments, evidence of metastases and intercurrent infection, palliative treatment, and any adverse reactions, including those to palliative treatment. The haemoglobin concentration and total white cell and platelet counts wvere measured, and chemotherapy was given, modified, or withheld as indicated by the results, or other toxicity.
RESULTS
Population in the study Between March 1975 and April 1977, 253 (125 Rt, 128 RtC3) patients were admitted from 16 centres within the UK. Of these patients, 17 (4 Rt, 13 RtC3) were excluded; in 11 the histology was not small-cell; 1 was incorrectly classified as having "limited" disease; I had intercurrent disease, and 4 were above the age Quality of life At 12 months (Table V) there were no important differences between the distributions of the general condition, the grade of physical activity or the grade of the respiratory assessment for the 2 series, although the number of survivors was small. The distributions based on the larger numbers at 3 and at 6 months (not tabulated here) were also similar for the 2 series. Although immediately after the pulse of chemotherapy some RtC3 patients
DISC USSION
The present study desigin was based on the results of the first MRC small-cell study (Fox & Scadding, 1973) and it compares the results of the better treatment from that study, radiotherapy alone, with those of the same treatment in combination with chemotherapy. Two points are worthy of note. First, the staging criteria for entry were not as exclusive as in the first study, for which only patients with clinically resectable tumours were eligible. Secondly, the first study did not define the radiation dose as clearly as the present study. In this study of 236 patients with smallcell carcinoma of the lung of "limited" extent, treatment with radiotherapy plus chemotherapy (RtC3) proved to be superior to treatment with radiotherapy alone (Rt). Over the 12-month period there was an increased survival as shown by the survival curves; the median survival was 43 weeks compared with 25 weeks, and at 12 months 3400 of the patients compared with 1800 were alive. In the RtC3 series 26% of the patients were alive and free from overt metastases at 12 months, but in the Rt series only 8%. Furthermore, metastases appeared earlier as well as more frequently in the Rt series, 7900 of the patients compared with 570o of RtC3 patients having developed metastases by 12 months. All these differences are statistically significant. Over 5000 of the patients in the Rt series received additional palliative therapy compared with only 19% in the RtC3 series, so that in practice the radiotherapy frequently had to be supplemented by additional radiotherapy or by chemotherapy.
Although the advantages from the addition of the adjuvant chemotherapy are clear-cut, they are somewhat disappointing in degree. Also the duration of followup is not yet long enough to show whether any worthwhile influence on long-term survival will be achieved. Failure to control the disease in the majority of patients may be ascribed to inadequate treatment of the primary disease and inability of the 3-drug regimen to control metastatic disease, particularly in the brain. In a substantial proportion of the patients neither therapy was adequate to eliminate the primary growth. Thus, of the 29 patients who had necropsy examinations among the 175 who died in the year, 11 of the 15 in the Rt series and 8 of the 14 in the RtC3 series had evidence of the primary growth at postmortem examination; thus there was no difference between the 2 series. A further 21 and 12, respectively, were reported to have died without necropsy with clinical or radiological evidence of persistence, extension or recurrence of the primary growth; again showing no difference between the 2 series. Altogether, 3000 of the patients who died had evidence of failure to control the primary growth. Although it might be expected that higher doses of radiation would have a greater effect on the primary growth, Deeley (1 966) found that the consequent radiation damage to the lungs reduced survival. It is not clear, therefore, whether results would have been improved by the choice of a higher radiation dose. In this respect it is relevant that recurrence at the primary site rarely seemed to be a major clinical problem since, of the 15 Rt and 14 RtC3 patients examined by necropsy, all but 2 and 3, respectively, had secondary deposits as well.
The choice of drugs was based on the report (Hansen et al., 1976) by Hansen et al. (1976) . The i.v. route was used to ensure patient compliance with the regimen and the dose was selected after an initial (unpublished) pilot study conducted by the Working Party.
Although CCNU undoubtedly contributed considerably to the toxicity of the regimen, it was felt important to include it for the above reason, and also because its lipid solubility permits good access across the blood-brain barrier (Livingston, 1976) . In the present study the drug regimen was not adequate to control metastases, and the differences between the two series in the frequency of metastases in individual organs were very small. The brain was equally involved in both series, so that CCNU did not prevent cerebral secondaries in this series, a disappointing finding. A similar failure has been reported by Alexander et al. (1977) , although in a summary of collected data from the literature, Bunn et al. (1977) 19 received extra pulses because they were responding, and even at 12 months 12 were still receiving pulses. It is usual for some degree of toxicity to be associated with such chemotherapy regimens and the present treatment was designed to be acceptable for outpatient use. In general this proved to be the case. In diseases where long-term survival is infrequent, the quality of life is particularly important but difficult to measure satisfactorily. Although the patients in the chemotherapy series frequently reported symptoms for hours after a pulse of chemotherapy, the assessments of the general condition, the degree of physical activity and respiratory function by a clinical grading showed no important difference between the 2 series at any time during the year. Of the survivors at one year, a substantial proportion were in good general condition, physically active and without undue dyspnoea on exertion.
We are unable to make a detailed com- Finally, a word of caution about the 3-drug schedule used in this present investigation is necessary. Before the series reported here, it had previously been tested in a pilot study in 50 patients with more extensive disease, and found to have an acceptable level of toxicity. However, in the new MRC study (Third MRC smallcell study) this same radiotherapy plus chemotherapy regimen has probably led to some deaths associated with intractable vomiting and dehydration. There have also been deaths attributed to toxicity after the first pulse of chemotherapy in patients who were allocated the same drugs in a regimen which differs only in that the radiotherapy is preceded by 2 pulses of chemotherapy at intervals of 3 weeks. However, increasing the fluid intake and giving the patient sodium bicarbonate tablets for 48 h starting on the day of each chemotherapy treatment appear to have reduced or eliminated the risk.
In conclusion, this study has shown that a 3-drug regimen of cyclophosphamide, methotrexate and CCNU, given after a relatively low dose of radiotherapy to the primary lesion, has improved the survival during 12 months' follow-up.
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